

**Claims**

1. A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser and an insulin secretagogue, to a mammal in need thereof.
2. A method according to claim 1, wherein the insulin secretagogue is a sulphonylurea.
3. A method according to claim 1, wherein the insulin secretagogue is glibenclamide, glipizide, gliclazide, glimepiride, tolazamide or tolbutamide.
4. A method according to any one of claims 1 to 3, wherein the insulin sensitiser is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound I).
5. A method according to any one of claims 1 to 4, which comprises the administration of 2 to 12 mg of Compound (I).
6. A method according to any one of claims 1 to 5, which comprises the administration of 2 to 4, 4 to 8 or 8 to 12 mg of Compound (I).
7. A method according to any one of claims 1 to 6, which comprises the administration of 2 to 4mg of Compound (I).
8. A method according to any one of claims 1 to 6, which comprises the method the administration of 4 to 8mg of Compound (I).
9. A method according to any one of claims 1 to 6, which comprises the administration of 8 to 12 mg of Compound (I).
10. A method according to any one of claims 1 to 6, which comprises the administration of 2 mg of Compound (I).

11. A method according to any one of claims 1 to 6, which comprises the administration of 4 mg of Compound (I).
12. A method according to any one of claims 1 to 6, which comprises the  
5 administration of 8 mg of Compound (I).
13. A method according to claim 1, wherein the insulin sensitiser is (+) -5-  
[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-  
yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (or troglitazone), 5-[4-[(1-  
10 methylcyclohexyl)methoxy]benzyl] thiazolidine-2,4-dione (or ciglitazone), 5-  
[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl] thiazolidine-2,4-dione (or  
pioglitazone) or 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-  
ylmethyl]thiazolidine-2,4-dione (or englitazone); or a pharmaceutically  
acceptable form thereof.
14. A pharmaceutical composition comprising an insulin sensitiser, an  
15 insulin secretagogue and a pharmaceutically acceptable carrier therefor.
15. A composition according to claim 14, wherein the insulin secretagogue is  
20 a sulphonylurea.
16. A composition according to claim 14 or claim 15, wherein the insulin  
secretagogue is glibenclamide, glipizide, gliclazide, glimepiride, tolazamide or  
25 tolbutamide.
17. A composition according to any one of claims 14 to 16, wherein the  
insulin sensitiser is Compound (I)
18. A composition according to any one of claims 14 to 17, which comprises  
30 2 to 12 mg of Compound (I).
19. A pharmaceutical composition comprising an insulin sensitiser an insulin  
secretagogue and a pharmaceutically acceptable carrier therefor, for use as an  
active therapeutic substance.

35

20. A pharmaceutical composition comprising an insulin sensitiser, an insulin secretagogue and a pharmaceutically acceptable carrier therefor, for use in the treatment of diabetes mellitus and conditions associated with diabetes mellitus.

5 21. A composition according to any one of claims 14, 20 or 21, wherein the insulin sensitiser is (+) -5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (or troglitazone), 5-[4-[(1-methylcyclohexyl)methoxy]benzyl] thiazolidine-2,4-  
10 dione (or ciglitazone), 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl] thiazolidine-2,4-dione (or pioglitazone) or 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-ylmethyl]thiazolidine-2,4-dione (or englitazone); or a pharmaceutically acceptable form thereof.